Yoshihiro Hattori - Concepedia

Author

Yoshihiro Hattori

Hyogo Prefectural Cancer Center

Also Known As

Hattori, Yoshihiro, Yoshihiro HATTORI, Yoshihiro Hattori

Publications

687

Citations

H-Index

Concepts

All Affiliations

Hyogo Prefectural Cancer Center National Hospital Organization Osaka International Cancer Institute Toneyama National Hospital National Hospital Organization Kyushu Cancer Center

About

Yoshihiro Hattori is an author at Hyogo Prefectural Cancer Center specializing in oncology, pathology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	166
2	Pathology	4	4	166
3	Immunology	2	2	63
4	Gastroenterology	1	1	35
5	Pharmacology	1	1	86

Yoshihiro Hattori

Publications

624

Citations

H-Index

Page 1

	Year	Citations
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, International Journal of Clinical Oncology	2019	145
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee, Journal of Clinical Oncology	2024	123
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial Takehito Shukuya, Takeharu Yamanaka, Takashi Seto, The Lancet Oncology Squamous Cell CarcinomaMedicinePharmacologyDocetaxel Versus CisplatinPathology	2015	86
Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study Hidehito Horinouchi, Naoyuki Nogami, Hideo Saka, Cancer Science	2021	54
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316) Motoko Tachihara, Shunichi Negoro, Takako Inoue, BMC Cancer	2018	38
Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer Yuichiro Yasuda, Yoshiko Urata, Rie Tohnai, Internal Medicine Immune-related Colitis InducedDysbiosisLung InflammationImmunologyGastroenterology	2017	35
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET) Shinji Takeuchi, Noriko Yanagitani, Takashi Seto, Translational Lung Cancer Research	2021	31
The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease Yuichiro Yasuda, Yoshihiro Hattori, Rie Tohnai, Japanese Journal of Clinical Oncology	2017	29
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). Tomoyuki Otsuka, Masahide Mori, Yukihiro Yano, PubMed	2015	28
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study Kentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, European Journal of Cancer MedicineImmunologyPathologyBronchial NeoplasmImmune Checkpoint Inhibitor	2021	28

Page 1